Fingolimod (FTY720), an immunomodulator that acts on sphingosine-1-phosphate receptors, is the first oral disease-modifying agent to be approved by the US FDA for the treatment of relapsing forms ...

The company's bid to block copycat versions of Gilenya (fingolimod) by China's HEC Pharm and other drugmakers was turned down ahead of the weekend, just days after the court reinstated an ...

Fingolimod is associated with a 0.5–0.6% of macular edema, usually presenting within the first 3–4 months; diagnosis usually requires optical coherence tomography and/or fluorescein angiography.

Ponesimod, alemtuzumab, teriflunomide, ozanimod, and fingolimod significantly reduce brain volume loss compared with placebo. Indirect treatment comparisons reveal varying impacts of disease ...

Still in the game, but just barely, is Basel–based Novartis' S1P1 modulator FTY720 (fingolimod), which has run into serious safety issues in pivotal testing. Table 1 Selected MS therapies in ...

Discontinuing natalizumab or fingolimod (Gilenya) carried the highest risks. In France, an analysis of registry data revealed ...

The prescribers preferred ponesimod over siponimod, fingolimod and ozanimod primarily because of the fewer drug-drug interactions, while the multiple sclerosis patients chose ponesimod because of the ...

The UK's National Institute for Clinical and Health Excellence has issued final draft guidance recommending the NHS to use Sanofi's Aubagio (teriflunomide) for adult patients with relapsing ...

Progressive Multifocal Leukoencephalopathy (PML) is a severe, life-threatening condition that poses a particular risk for MS ...

导读 2024年欧洲多发性硬化研究和治疗委员会大会（ECTRIMS ...